Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 9Terminated 8Unknown 5Recruiting 4Active not recruiting 4Not yet recruiting 1

Sponsor Class

OTHER 4OTHER_GOV 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Thoracic 5

Conditions

Breast Neoplasms 1871Neoplasms 1257Colorectal Neoplasms 1057Carcinoma, Non-Small-Cell Lung 1012Stomach Neoplasms 802Carcinoma, Hepatocellular 785Lung Neoplasms 769Prostatic Neoplasms 697Pancreatic Neoplasms 577Rectal Neoplasms 449Ovarian Neoplasms 406Colonic Neoplasms 405Neoplasm Metastasis 403Uterine Cervical Neoplasms 400Recurrence 382Leukemia, Myeloid, Acute 372Esophageal Neoplasms 363Multiple Myeloma 339Lymphoma 335Head and Neck Neoplasms 330Melanoma 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 292Brain Neoplasms 264Urinary Bladder Neoplasms 256Liver Neoplasms 225Nasopharyngeal Carcinoma 223Leukemia 218Lymphoma, Large B-Cell, Diffuse 216Polycystic Ovary Syndrome 210Squamous Cell Carcinoma of Head and Neck 205

Interventions

sotorasib 1pembrolizumab 1Vinorelbine 1Radiosurgery 1Pemetrexed 1GC Temporary Stopping 1Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Non-small Cell Lung Cancer Metastatic × Clear all
NCT06127940 2023-11-13

K-SAB

Karolinska University Hospital

Phase 1 Unknown
20 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

NCT04082182 2021-03-30

MIDRIX4-LUNG

University Hospital, Ghent

Phase 1 Unknown
7 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

NCT03656094 2019-12-09

Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

Samsung Medical Center

Phase 2 Unknown
98 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

NCT02041468 2017-08-30

Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

Jewish General Hospital

Unknown
29 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

NCT03240549 2017-08-07

Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease

Beijing Hospital

Phase 2 Unknown
159 enrolled
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡